Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
ORAP
Overview
What is ORAP?
ORAP (pimozide) is an orally active antipsychotic agent of the diphenyl-butylpiperidine series. The structural formula of pimozide, 1-[1-[4,4-bis(4-fluorophenyl)butyl]-4-piperidinyl]-1,3-dihydro-2H-benzimidazole-2-one is:
The solubility of pimozide in water is less than 0.01 mg/mL; it is slightly soluble in most organic solvents.
Each white ORAP tablet contains either 1 mg or 2 mg of pimozide and the following inactive ingredients: calcium stearate, microcrystalline cellulose, lactose anhydrous and corn starch.
What does ORAP look like?
What are the available doses of ORAP?
Sorry No records found.
What should I talk to my health care provider before I take ORAP?
Sorry No records found
How should I use ORAP?
ORAP (pimozide) is indicated for the suppression of motor and phonic tics in patients with Tourette’s Disorder who have failed to respond satisfactorily to standard treatment. ORAP is not intended as a treatment of first choice nor is it intended for the treatment of tics that are merely annoying or cosmetically troublesome. ORAP should be reserved for use in Tourette’s Disorder patients whose development and/or daily life function is severely compromised by the presence of motor and phonic tics.
Evidence supporting approval of pimozide for use in Tourette’s Disorder was obtained in two controlled clinical investigations which enrolled patients between the ages of 8 and 53 years. Most subjects in the two trials were 12 or older.
The suppression of tics by ORAP requires a slow and gradual introduction of the drug. The patient’s dose should be carefully adjusted to a point where the suppression of tics and the relief afforded is balanced against the untoward side effects of the drug.
An ECG should be done at baseline and periodically thereafter, especially during the period of dose adjustment (see and ). Periodic attempts should be made to reduce the dosage of ORAP to see whether or not tics persist at the level and extent first identified. In attempts to reduce the dosage of ORAP, consideration should be given to the possibility that increases of tic intensity and frequency may represent a transient, withdrawal-related phenomenon rather than a return of disease symptoms. Specifically, one to two weeks should be allowed to elapse before one concludes that an increase in tic manifestations is a function of the underlying disease syndrome rather than a response to drug withdrawal. A gradual withdrawal is recommended in any case.
What interacts with ORAP?
- Because azole antifungal agents are also inhibitors of the CYP 3A4 enzymes and thus may likewise impair pimozide metabolism, ORAP is contraindicated in patients receiving the azole antifungal agents itraconazole and ketoconazole.
- 1.
- 2.
- Array
- PRECAUTIONS - Drug Interactions
- 4.
- 5.
- 6.
- Array
- Precautions - Drug Interactions - Pimozide and Celexa
- Array
- PRECAUTIONS – Drug Interactions
- Array
- PRECAUTIONS – Drug Interactions
- Similarly, protease inhibitor drugs are also inhibitors of CYP 3A4, and thus ORAP is contraindicated in patients receiving protease inhibitors such as ritonavir, saquinovir, indinavir, and nelfinavir. (See ).
- Nefazodone is a potent inhibitor of CYP 3A4, and its concomitant use with ORAP is also contraindicated.
- Other drugs that are relatively less potent inhibitors of CYP 3A4 should also be avoided, in view of the risks: e.g. zileuton, fluvoxamine.
What are the warnings of ORAP?
3. Desmopressin Acetate Tablets should be used with caution in patients with habitual or psychogenic polydipsia who may be more likely to drink excessive amounts of water, putting them at greater risk of hyponatremia.
Tardive Dyskinesia
A syndrome consisting of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to rely upon prevalence estimates to predict, at the inception of antipsychotic treatment, which patients are likely to develop the syndrome. Whether antipsychotic drug products differ in their potential to cause tardive dyskinesia is unknown.
Both the risk of developing tardive dyskinesia and the likelihood that it will become irreversible are believed to increase as the duration of treatment and the total cumulative dose of antipsychotic drugs administered to the patient increase. However, the syndrome can develop, although much less commonly, after relatively brief treatment periods at low doses.
There is no known treatment for established cases of tardive dyskinesia, although the syndrome may remit, partially or completely, if antipsychotic treatment is withdrawn. Antipsychotic treatment itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome and thereby may possibly mask the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown.
Given these considerations, antipsychotic drugs should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that, 1) is known to respond to antipsychotic drugs, and, 2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.
If signs and symptoms of tardive dyskinesia appear in a patient on antipsychotics, drug discontinuation should be considered. However, some patients may require treatment despite the presence of the syndrome.
(For further information about the description of tardive dyskinesia and its clinical detection, please refer to ).
Neuroleptic Malignant Syndrome (NMS)
A potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with antipsychotic drugs. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status (including catatonic signs) and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmias). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis) and acute renal failure.
The diagnostic evaluation of patients with this syndrome is complicated. In arriving at a diagnosis, it is important to identify cases where the clinical presentation includes both serious medical illness (e.g., pneumonia, systemic infection, etc.) and untreated or inadequately treated extrapyramidal signs and symptoms (EPS). Other important considerations in the differential diagnosis include central anticholinergic toxicity, heat stroke, drug fever and primary central nervous system (CNS) pathology.
The management of NMS should include 1) immediate discontinuation of antipsychotic drugs and other drugs not essential to concurrent therapy, 2) intensive symptomatic treatment and medical monitoring, and 3) treatment of any concomitant serious medical problems for which specific treatments are available. There is no general agreement about specific pharmacological treatment regimens for uncomplicated NMS.
If a patient requires antipsychotic drug treatment after recovery from NMS, the potential reintroduction of drug therapy should be carefully considered. The patient should be carefully monitored, since recurrences of NMS have been reported.
Hyperpyrexia, not associated with the above symptom complex, has been reported with other antipsychotic drugs.
Other
Sudden, unexpected deaths have occurred in experimental studies of conditions other than Tourette’s Disorder. These deaths occurred while patients were receiving dosages in the range of 1 mg per kg. One possible mechanism for such deaths is prolongation of the QT interval predisposing patients to ventricular arrhythmia. An electrocardiogram should be performed before ORAP treatment is initiated and periodically thereafter, especially during the period of dose adjustment.
ORAP may have a tumorigenic potential. Based on studies conducted in mice, it is known that pimozide can produce a dose-related increase in pituitary tumors. The full significance of this finding is not known, but should be taken into consideration in the physician’s and patient’s decisions to use this drug product. This finding should be given special consideration when the patient is young and chronic use of pimozide is anticipated (see ).
What are the precautions of ORAP?
Leukopenia, Neutropenia and Agranulocytosis
General
ORAP (pimozide) may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks, such as driving a car or operating machinery, especially during the first few days of therapy.
ORAP produces anticholinergic side effects and should be used with caution in individuals whose conditions may be aggravated by anticholinergic activity.
ORAP should be administered cautiously to patients with impairment of liver or kidney function, because it is metabolized by the liver and excreted by the kidneys.
Antipsychotics should be administered with caution to patients receiving anticonvulsant medication, with a history of seizures, or with EEG abnormalities, because they may lower the convulsive threshold. If indicated, adequate anticonvulsant therapy should be maintained concomitantly.
Information for Patients
Treatment with ORAP exposes the patient to serious risks. A decision to use ORAP chronically in Tourette’s Disorder is one that deserves full consideration by the patient (or patient’s family) as well as by the treating physician. Because the goal of treatment is symptomatic improvement, the patient’s view of the need for treatment and assessment of response are critical in evaluating the impact of therapy and weighing its benefits against the risks. Since the physician is the primary source of information about the use of a drug in any disease, it is recommended that the following information be discussed with patients and/or their families.
ORAP is intended only for use in patients with Tourette’s Disorder whose symptoms are severe and who cannot tolerate, or who do not respond to HALDOL (haloperidol).
Given the likelihood that a proportion of patients exposed chronically to antipsychotics will develop tardive dyskinesia, it is advised that all patients in whom chronic use is contemplated be given, if possible, full information about this risk. The decision to inform patients and/or their guardians must obviously take into account the clinical circumstances and the competency of the patient to understand the information provided.
There is limited information available on the use of ORAP in children under 12 years of age.
The information available on ORAP from foreign marketing experience and from U.S. clinical trials indicates that ORAP has a side effect profile similar to that of other antipsychotic drugs. Patients should be informed that all types of side effects associated with the use of antipsychotics may be associated with the use of ORAP.
In addition, sudden, unexpected deaths have occurred in patients taking high doses of ORAP for conditions other than Tourette’s Disorder. These deaths may have been the result of an effect of ORAP upon the heart. Therefore, patients should be instructed not to exceed the prescribed dose of ORAP and they should realize the need for the initial ECG and for follow-up ECGs during treatment.
Also, pimozide, at a dose about 15 times that given humans, caused an increase in the number of benign tumors of the pituitary gland in female mice. It is not possible to say how important this is. Similar tumors were not seen in rats given pimozide, nor at lower doses in mice, which is reassuring. However, any such finding must be considered to suggest a possible risk of long term use of the drug.
Because substances in grapefruit juice may inhibit the metabolism of pimozide by CYP 3A4, patients should be advised to avoid grapefruit juice.
Laboratory Tests
An ECG should be done at baseline and periodically thereafter throughout the period of dose adjustment. Any indication of prolongation of QTc interval beyond an absolute limit of 0.47 seconds (children) or 0.52 seconds (adults), or more than 25% above the patient’s original baseline should be considered a basis for stopping further dose increase (see ) and considering a lower dose.
Since hypokalemia has been associated with ventricular arrhythmias, potassium insufficiency, secondary to diuretics, diarrhea, or other cause, should be corrected before ORAP therapy is initiated and normal potassium maintained during therapy.
Drug Interactions
Because ORAP prolongs the QT interval of the electrocardiogram, an additive effect on QT interval would be anticipated if administered with other drugs, such as phenothiazines, tricyclic antidepressants or antiarrhythmic agents, which prolong the QT interval. Accordingly, pimozide should not be given with dofetilide, sotalol, quinidine, other Class Ia and III anti-arrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron mesylate, probucol, tacrolimus, ziprasidone, or other drugs that have demonstrated QT prolongation as one of their pharmacodynamic effects. Also, the use of macrolide antibiotics in patients with prolonged QT intervals has been rarely associated with ventricular arrhythmias. Such concomitant administration should not be undertaken (see ).
Since ORAP is partly metabolized via CYP 3A4, it should not be administered concomitantly with inhibitors of this metabolic system, such as azole antifungal agents and protease inhibitor drugs (see ).
Pimozide and Celexa: In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone. Racemic citalopram did not alter the mean AUC or C of pimozide. The mechanism of this pharmacodynamic interaction is not known. Concomitant use of pimozide and Celexa or Lexapro is contraindicated (See ).
CYP 2D6 inhibitors: In healthy subjects, co-administration of pimozide 2 mg (single dose) and paroxetine 60 mg resulted in a 151% increase in pimozide AUC and a 62% increase in pimozide Cmax compared to pimozide administered alone. The increase in pimozide AUC and Cmax is related to the CYP 2D6 inhibitory properties of paroxetine. Concomitant use of pimozide and paroxetine or other strong CYP 2D6 inhibitors are contraindicated (see ). As CYP 1A2 may also contribute to the metabolism of ORAP, prescribers should be aware of the theoretical potential for drug interactions with inhibitors of this enzymatic system.
ORAP may be capable of potentiating CNS depressants, including analgesics, sedatives, anxiolytics, and alcohol.
Rare case reports have suggested possible additive effects of pimozide and fluoxetine leading to bradycardia.
Concomitant administration of pimozide and sertraline should be contraindicated (See ).
Pharmacogenomics
Individuals with genetic variations resulting in poor CYP 2D6 metabolism (approximately 5 to 10% of the population) exhibit higher pimozide concentrations than extensive CYP 2D6 metabolizers. The concentrations observed in poor CYP 2D6 metabolizers are similar to those seen with strong CYP 2D6 inhibitors such as paroxetine. The time to achieve steady state pimozide concentrations is expected to be longer (approximately 2 weeks) in poor CYP 2D6 metabolizers because of the prolonged half-life. Alternative dosing strategies are recommended in patients who are genetically poor CYP 2D6 metabolizers (see ).
Interaction with Food
Patients should avoid grapefruit juice because it may inhibit the metabolism of pimozide by CYP 3A4.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Carcinogenicity studies were conducted in mice and rats. In mice, pimozide causes a dose-related increase in pituitary and mammary tumors.
When mice were treated for up to 18 months with pimozide, pituitary gland changes developed in females only. These changes were characterized as hyperplasia at doses approximating the human dose and adenoma at doses about fifteen times the maximum recommended human dose on a mg per kg basis. The mechanism for the induction of pituitary tumors in mice is not known.
Mammary gland tumors in female mice were also increased, but these tumors are expected in rodents treated with antipsychotic drugs which elevate prolactin levels. Chronic administration of an antipsychotic also causes elevated prolactin levels in humans. Tissue culture experiments indicate that approximately one-third of human breast cancers are prolactin-dependent , a factor of potential importance if the prescription of these drugs is contemplated in a patient with a previously detected breast cancer. Although disturbances such as galactorrhea, amenorrhea, gynecomastia, and impotence have been reported with antipsychotic drugs, the clinical significance of elevated serum prolactin levels is unknown for most patients. Neither clinical studies nor epidemiologic studies conducted to date have shown an association between chronic administration of these drugs and mammary tumorigenesis. The available evidence, however, is considered too limited to be conclusive at this time.
In a 24-month carcinogenicity study in rats, animals received up to 50 times the maximum recommended human dose. No increased incidence of overall tumors or tumors at any site was observed in either sex. Because of the limited number of animals surviving this study, the meaning of these results is unclear.
Pimozide did not have mutagenic activity in the Ames test with four bacterial test strains, in the mouse dominant lethal test or in the micronucleus test in rats.
Reproduction studies in animals were not adequate to assess all aspects of fertility. Nevertheless, female rats administered pimozide had prolonged estrus cycles, an effect also produced by other antipsychotic drugs.
Pregnancy
Labor and Delivery
This drug has no recognized use in labor or delivery.
Nursing Mothers
It is not known whether pimozide is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for tumorigenicity and unknown cardiovascular effects in the infant, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Pediatric Use
Although Tourette's Disorder most often has its onset between the ages of 2 and 15 years, information on the use and efficacy of ORAP in patients less than 12 years of age is limited. A 24-week open label study in 36 children between the ages of 2 and 12 demonstrated that pimozide has a similar safety profile in this age group as in older patients and there were no safety findings that would preclude its use in this age group.
Because its use and safety have not been evaluated in other childhood disorders, ORAP is not recommended for use in any condition other than Tourette’s Disorder.
What are the side effects of ORAP?
General
Clinical Trials
- Array
- Array
- Array
- Array
- Array
- Array
- Array
- Array
- Array
- Array
- Array
The following adverse reaction tabulation was derived from 20 patients in a 6-week long placebo-controlled clinical trial of ORAP in Tourette’s Disorder.
Body System/
Pimozide
Placebo
Adverse Reaction
(N = 20)
(N = 20)
Body as a Whole
Headache 1 2
Gastrointestinal
Dry Mouth 5 1
Diarrhea 1 0
Nausea 0 2
Vomiting 0 1
Constipation 4 2
Eructations 0 1
Thirsty 1 0
Appetite increase 1 0
Endocrine
Menstrual disorder 0 1
Breast secretions 0 1
Musculoskeletal
Muscle cramps 0 1
Muscle tightness 3 0
Stooped posture 2 0
CNS
Drowsiness 7 3
Sedation 14 5
Insomnia 2 2
Dizziness 0 1
Akathisia 8 0
Rigidity 2 0
Speech disorder 2 0
Handwriting change 1 0
Akinesia 8 0
Psychiatric
Depression 2 3
Excitement 0 1
Nervous 1 0
Adverse behavior effect 5 0
Special Senses
Visual disturbance 4 0
Taste change 1 0
Sensitivity of eyes to light 1 0
Decrease accommodation 4 1
Spots before eyes 0 1
Urogenital
Impotence 3 0
The following adverse event tabulation was derived from 36 children (age 2 to 12) in a 24-week open trial of ORAP in Tourette’s Disorder.
Body System/ Number of Patients
Adverse Reaction
Experiencing Each Event (%)
All Events
Drug-Related
Events
(N=36) (N=36)
Body as a Whole
Gastrointestinal
Musculoskeletal
Central Nervous System
Psychiatric
Skin
Special Senses
Cardiovascular
Because clinical investigational experience with ORAP in Tourette’s Disorder is limited, uncommon adverse reactions may not have been detected. The physician should consider that other adverse reactions associated with antipsychotics may occur.
Other Adverse Reactions
In addition to the adverse reactions listed above, those listed below have been reported in U.S. clinical trials of ORAP in conditions other than Tourette’s Disorder.
Body as a Whole:
Cardiovascular/Respiratory:
Gastrointestinal:
Endocrine:
Metabolic/Nutritional:
Central Nervous System:
Psychiatric:
Skin:
Special Senses:
Urogenital:
Postmarketing Reports
The following experiences were described in spontaneous postmarketing reports. These reports do not provide sufficient information to establish a clear causal relationship with the use of ORAP.
Gastrointestinal:
Hematologic:
Metabolic/Nutritional:
Other:
What should I look out for while using ORAP?
Because azole antifungal agents are also inhibitors of the CYP 3A4 enzymes and thus may likewise impair pimozide metabolism, ORAP is contraindicated in patients receiving the azole antifungal agents itraconazole and ketoconazole.
Similarly, protease inhibitor drugs are also inhibitors of CYP 3A4, and thus ORAP is contraindicated in patients receiving protease inhibitors such as ritonavir, saquinovir, indinavir, and nelfinavir. (See ).
Nefazodone is a potent inhibitor of CYP 3A4, and its concomitant use with ORAP is also contraindicated.
Other drugs that are relatively less potent inhibitors of CYP 3A4 should also be avoided, in view of the risks: e.g. zileuton, fluvoxamine.
The use of ORAP (pimozide) in the treatment of Tourette’s Disorder involves different risk/benefit considerations than when antipsychotic drugs are used to treat other conditions. Consequently, a decision to use ORAP should take into consideration the following (see also ).
What might happen if I take too much ORAP?
In general, the signs and symptoms of overdosage with ORAP (pimozide) would be an exaggeration of known pharmacologic effects and adverse reactions, the most prominent of which would be: 1) electrocardiographic abnormalities, 2) severe extrapyramidal reactions, 3) hypotension, 4) a comatose state with respiratory depression.
In the event of overdosage, gastric lavage, establishment of a patent airway and, if necessary, mechanically-assisted respiration are advised. Electrocardiographic monitoring should commence immediately and continue until the ECG parameters are within the normal range. Hypotension and circulatory collapse may be counteracted by use of intravenous fluids, plasma, or concentrated albumin, and vasopressor agents such as metaraminol, phenylephrine and norepinephrine.
Epinephrine should not be used. In case of severe extrapyramidal reactions, antiparkinson medication should be administered. Because of the long half-life of pimozide, patients who take an overdose should be observed for at least 4 days. As with all drugs, the physician should consider contacting a poison control center for additional information on the treatment of overdose.
How should I store and handle ORAP?
ORAP (pimozide) 1 mg tablets are white, oval tablets, debossed “ORAP 1”, partially scored on one side and scored on the other. They are available in bottles of 100 (NDC 57844-151-01).ORAP (pimozide) 2 mg tablets are white, oval tablets, debossed “ORAP 2”, partially scored on one side and scored on the other. They are available in bottles of 100 (NDC 57844-198-01).Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container as defined in the official compendium.Pharmacist: Dispense in child-resistant container.Manufactured in Croatia by:PLIVA HRVATSKA d.o.o.Zagreb, CroatiaManufactured for:Teva Select Brands, Division of Teva Pharmaceuticals USARev. S 3/2014ORAP (pimozide) 1 mg tablets are white, oval tablets, debossed “ORAP 1”, partially scored on one side and scored on the other. They are available in bottles of 100 (NDC 57844-151-01).ORAP (pimozide) 2 mg tablets are white, oval tablets, debossed “ORAP 2”, partially scored on one side and scored on the other. They are available in bottles of 100 (NDC 57844-198-01).Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container as defined in the official compendium.Pharmacist: Dispense in child-resistant container.Manufactured in Croatia by:PLIVA HRVATSKA d.o.o.Zagreb, CroatiaManufactured for:Teva Select Brands, Division of Teva Pharmaceuticals USARev. S 3/2014ORAP (pimozide) 1 mg tablets are white, oval tablets, debossed “ORAP 1”, partially scored on one side and scored on the other. They are available in bottles of 100 (NDC 57844-151-01).ORAP (pimozide) 2 mg tablets are white, oval tablets, debossed “ORAP 2”, partially scored on one side and scored on the other. They are available in bottles of 100 (NDC 57844-198-01).Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container as defined in the official compendium.Pharmacist: Dispense in child-resistant container.Manufactured in Croatia by:PLIVA HRVATSKA d.o.o.Zagreb, CroatiaManufactured for:Teva Select Brands, Division of Teva Pharmaceuticals USARev. S 3/2014ORAP (pimozide) 1 mg tablets are white, oval tablets, debossed “ORAP 1”, partially scored on one side and scored on the other. They are available in bottles of 100 (NDC 57844-151-01).ORAP (pimozide) 2 mg tablets are white, oval tablets, debossed “ORAP 2”, partially scored on one side and scored on the other. They are available in bottles of 100 (NDC 57844-198-01).Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container as defined in the official compendium.Pharmacist: Dispense in child-resistant container.Manufactured in Croatia by:PLIVA HRVATSKA d.o.o.Zagreb, CroatiaManufactured for:Teva Select Brands, Division of Teva Pharmaceuticals USARev. S 3/2014ORAP (pimozide) 1 mg tablets are white, oval tablets, debossed “ORAP 1”, partially scored on one side and scored on the other. They are available in bottles of 100 (NDC 57844-151-01).ORAP (pimozide) 2 mg tablets are white, oval tablets, debossed “ORAP 2”, partially scored on one side and scored on the other. They are available in bottles of 100 (NDC 57844-198-01).Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container as defined in the official compendium.Pharmacist: Dispense in child-resistant container.Manufactured in Croatia by:PLIVA HRVATSKA d.o.o.Zagreb, CroatiaManufactured for:Teva Select Brands, Division of Teva Pharmaceuticals USARev. S 3/2014ORAP (pimozide) 1 mg tablets are white, oval tablets, debossed “ORAP 1”, partially scored on one side and scored on the other. They are available in bottles of 100 (NDC 57844-151-01).ORAP (pimozide) 2 mg tablets are white, oval tablets, debossed “ORAP 2”, partially scored on one side and scored on the other. They are available in bottles of 100 (NDC 57844-198-01).Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container as defined in the official compendium.Pharmacist: Dispense in child-resistant container.Manufactured in Croatia by:PLIVA HRVATSKA d.o.o.Zagreb, CroatiaManufactured for:Teva Select Brands, Division of Teva Pharmaceuticals USARev. S 3/2014ORAP (pimozide) 1 mg tablets are white, oval tablets, debossed “ORAP 1”, partially scored on one side and scored on the other. They are available in bottles of 100 (NDC 57844-151-01).ORAP (pimozide) 2 mg tablets are white, oval tablets, debossed “ORAP 2”, partially scored on one side and scored on the other. They are available in bottles of 100 (NDC 57844-198-01).Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container as defined in the official compendium.Pharmacist: Dispense in child-resistant container.Manufactured in Croatia by:PLIVA HRVATSKA d.o.o.Zagreb, CroatiaManufactured for:Teva Select Brands, Division of Teva Pharmaceuticals USARev. S 3/2014ORAP (pimozide) 1 mg tablets are white, oval tablets, debossed “ORAP 1”, partially scored on one side and scored on the other. They are available in bottles of 100 (NDC 57844-151-01).ORAP (pimozide) 2 mg tablets are white, oval tablets, debossed “ORAP 2”, partially scored on one side and scored on the other. They are available in bottles of 100 (NDC 57844-198-01).Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container as defined in the official compendium.Pharmacist: Dispense in child-resistant container.Manufactured in Croatia by:PLIVA HRVATSKA d.o.o.Zagreb, CroatiaManufactured for:Teva Select Brands, Division of Teva Pharmaceuticals USARev. S 3/2014ORAP (pimozide) 1 mg tablets are white, oval tablets, debossed “ORAP 1”, partially scored on one side and scored on the other. They are available in bottles of 100 (NDC 57844-151-01).ORAP (pimozide) 2 mg tablets are white, oval tablets, debossed “ORAP 2”, partially scored on one side and scored on the other. They are available in bottles of 100 (NDC 57844-198-01).Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container as defined in the official compendium.Pharmacist: Dispense in child-resistant container.Manufactured in Croatia by:PLIVA HRVATSKA d.o.o.Zagreb, CroatiaManufactured for:Teva Select Brands, Division of Teva Pharmaceuticals USARev. S 3/2014ORAP (pimozide) 1 mg tablets are white, oval tablets, debossed “ORAP 1”, partially scored on one side and scored on the other. They are available in bottles of 100 (NDC 57844-151-01).ORAP (pimozide) 2 mg tablets are white, oval tablets, debossed “ORAP 2”, partially scored on one side and scored on the other. They are available in bottles of 100 (NDC 57844-198-01).Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container as defined in the official compendium.Pharmacist: Dispense in child-resistant container.Manufactured in Croatia by:PLIVA HRVATSKA d.o.o.Zagreb, CroatiaManufactured for:Teva Select Brands, Division of Teva Pharmaceuticals USARev. S 3/2014ORAP (pimozide) 1 mg tablets are white, oval tablets, debossed “ORAP 1”, partially scored on one side and scored on the other. They are available in bottles of 100 (NDC 57844-151-01).ORAP (pimozide) 2 mg tablets are white, oval tablets, debossed “ORAP 2”, partially scored on one side and scored on the other. They are available in bottles of 100 (NDC 57844-198-01).Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container as defined in the official compendium.Pharmacist: Dispense in child-resistant container.Manufactured in Croatia by:PLIVA HRVATSKA d.o.o.Zagreb, CroatiaManufactured for:Teva Select Brands, Division of Teva Pharmaceuticals USARev. S 3/2014ORAP (pimozide) 1 mg tablets are white, oval tablets, debossed “ORAP 1”, partially scored on one side and scored on the other. They are available in bottles of 100 (NDC 57844-151-01).ORAP (pimozide) 2 mg tablets are white, oval tablets, debossed “ORAP 2”, partially scored on one side and scored on the other. They are available in bottles of 100 (NDC 57844-198-01).Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].Dispense in a tight, light-resistant container as defined in the official compendium.Pharmacist: Dispense in child-resistant container.Manufactured in Croatia by:PLIVA HRVATSKA d.o.o.Zagreb, CroatiaManufactured for:Teva Select Brands, Division of Teva Pharmaceuticals USARev. S 3/2014
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
ORAP (pimozide) is an orally active antipsychotic drug product which shares with other antipsychotics the ability to blockade dopaminergic receptors on neurons in the central nervous system. Although its exact mode of action has not been established, the ability of pimozide to suppress motor and phonic tics in Tourette’s Disorder is thought to be a function of its dopaminergic blocking activity. However, receptor blockade is often accompanied by a series of secondary alterations in central dopamine metabolism and function which may contribute to both pimozide’s therapeutic and untoward effects. In addition, pimozide, in common with other antipsychotic drugs, has various effects on other central nervous system receptor systems which are not fully characterized.
Non-Clinical Toxicology
Because azole antifungal agents are also inhibitors of the CYP 3A4 enzymes and thus may likewise impair pimozide metabolism, ORAP is contraindicated in patients receiving the azole antifungal agents itraconazole and ketoconazole.Similarly, protease inhibitor drugs are also inhibitors of CYP 3A4, and thus ORAP is contraindicated in patients receiving protease inhibitors such as ritonavir, saquinovir, indinavir, and nelfinavir. (See ).
Nefazodone is a potent inhibitor of CYP 3A4, and its concomitant use with ORAP is also contraindicated.
Other drugs that are relatively less potent inhibitors of CYP 3A4 should also be avoided, in view of the risks: e.g. zileuton, fluvoxamine.
The use of ORAP (pimozide) in the treatment of Tourette’s Disorder involves different risk/benefit considerations than when antipsychotic drugs are used to treat other conditions. Consequently, a decision to use ORAP should take into consideration the following (see also ).
Because ORAP prolongs the QT interval of the electrocardiogram, an additive effect on QT interval would be anticipated if administered with other drugs, such as phenothiazines, tricyclic antidepressants or antiarrhythmic agents, which prolong the QT interval. Accordingly, pimozide should not be given with dofetilide, sotalol, quinidine, other Class Ia and III anti-arrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron mesylate, probucol, tacrolimus, ziprasidone, or other drugs that have demonstrated QT prolongation as one of their pharmacodynamic effects. Also, the use of macrolide antibiotics in patients with prolonged QT intervals has been rarely associated with ventricular arrhythmias. Such concomitant administration should not be undertaken (see ).
Since ORAP is partly metabolized via CYP 3A4, it should not be administered concomitantly with inhibitors of this metabolic system, such as azole antifungal agents and protease inhibitor drugs (see ).
Pimozide and Celexa: In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone. Racemic citalopram did not alter the mean AUC or C of pimozide. The mechanism of this pharmacodynamic interaction is not known. Concomitant use of pimozide and Celexa or Lexapro is contraindicated (See ).
CYP 2D6 inhibitors: In healthy subjects, co-administration of pimozide 2 mg (single dose) and paroxetine 60 mg resulted in a 151% increase in pimozide AUC and a 62% increase in pimozide Cmax compared to pimozide administered alone. The increase in pimozide AUC and Cmax is related to the CYP 2D6 inhibitory properties of paroxetine. Concomitant use of pimozide and paroxetine or other strong CYP 2D6 inhibitors are contraindicated (see ). As CYP 1A2 may also contribute to the metabolism of ORAP, prescribers should be aware of the theoretical potential for drug interactions with inhibitors of this enzymatic system.
ORAP may be capable of potentiating CNS depressants, including analgesics, sedatives, anxiolytics, and alcohol.
Rare case reports have suggested possible additive effects of pimozide and fluoxetine leading to bradycardia.
Concomitant administration of pimozide and sertraline should be contraindicated (See ).
Class Effect:
Possible risk factors for leukopenia/neutropenia include preexisting low white blood cell count (WBC) and history of drug induced leukopenia/neutropenia. Patients with a history of a clinically significant low WBC or drug induced leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and discontinuation of ORAP should be considered at the first sign of a clinically significant decline in WBC in the absence of other causative factors.
Patients with clinically significant neutropenia should be carefully monitored for fever or other symptoms or signs of infection and treated promptly if such symptoms or signs occur. Patients with severe neutropenia (absolute neutrophil count <1000/mm) should discontinue ORAP and have their WBC followed until recovery.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
518Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).